Publications by authors named "M Chinen"
This report introduces a novel approach to providing nutritional guidance for people dining out, utilizing takeout meals as a practical tool. The method comprises several essential steps: 1) Preparing takeout versions of restaurant dishes and bringing them to the hospital, 2) performing comprehensive nutritional evaluations of these meals and adjusting them as necessary to meet specific dietary needs, and 3) assessing the impact of these modified meals on post-meal blood glucose levels. This assessment is achieved through continuous blood glucose monitoring at crucial time points: before the meal, 60 minutes after beginning the meal, and 120 minutes after eating.
View Article and Find Full Text PDFAim: Real-world data (RWD) for paliperidone palmitate (PP) three-monthly (PP3M) is lacking based on Japan label requirements. This study evaluated the clinical effectiveness of PP3M versus PP once-monthly (PP1M) in patients with schizophrenia administered according to Japan label requirements.
Methods: Retrospective analyses were conducted using RWD from Merative™ MarketScan® Multi-State Medicaid (MDCD) claims database (June 2015-December 2022).
Article Synopsis
- * A renal biopsy indicated thrombotic microangiopathy (TMA), characterized by clots in small blood vessels, while cardiac tests revealed significant artery narrowing and heart muscle disease.
- * High levels of amphetamines and methamphetamines were detected in his blood, suggesting a potential link between methamphetamine use and the observed organ dysfunction and kidney damage.
Background: Spinal muscular atrophy (SMA) is an autosomal recessive genetic neuromuscular disorder with progressive muscle weakness and atrophy, mainly caused by lower motor neuron degeneration resulting from decreased levels of the survival motor neuron protein. Recently, 3 disease-modifying therapies for SMA (nusinersen, onasemnogene abeparvovec, and risdiplam) were approved in Japan that are expected to improve the prognosis of patients with SMA. Long-term clinical follow-up of adult patients treated with disease-modifying therapies and the natural history of SMA are essential to assess the real-world effectiveness of available treatments.
View Article and Find Full Text PDFObjective: This study evaluated the feasibility of a matching-pair test using eye-tracking technology to assess nusinersen effectiveness in patients with advanced spinal muscular atrophy (SMA) type I.
Methods: This prospective, observational study enrolled patients with 5q-SMA type I who had lost gross motor function. Three different levels of matching-pair tests were conducted using the eye-gaze system (My Tobii; TobiiDynavox Inc.